EGFR-mutant non-small cell lung cancer - Globe Thesis

Keyword [EGFR-mutant non-small cell lung cancer] Result: 1 - 18 \| Page: 1 of 1
1.	Novel Approaches To Overcome HGF-mediated Resistance To Gefitinib In EGFR Mutant Non-small Cell Lung Cancer Cells
2.	Mechanisms And Strategies On Drug Resistance Of EGFR-mutant Non-small Cell Lung Cancer
3.	Efficacy And Safety Of Stereotactic Body Radiation Therapy In The Management Of Oligopersistent Disease In Patients With Egfr Mutant Non-small Cell Lung Cancer During EGFR-TKIs Treatment
4.	Suppressed Expression Of Cbl-b By NF-κB Mediates Icotinib Resistance In EGFR-mutant Non-Small-Cell Lung Cancer
5.	Effect Analysis Of EGFR-TKIs Or Chemotherapy Combined With Radiotherapy In The Treatment Of Brain Metastases Of EGFR Mutant Non-small Cell Lung Cancer
6.	Meta-analysis Of EGFR-TKIs In EGFR-mutant Non-small Cell Lung Cancer Patients And Clinical Retrospective Validation
7.	Application Of Osimertinib In EGFR-mutant Non-small Cell Lung Cancer With Leptomeningeal Metastases
8.	EGFR-TKIs Resistances Increase PD-L1 Expression And Promote De Novo Synthesis Of Fatty Acid In EGFR Mutant Non-Small Cell Lung Cancer
9.	To Explore The Appropriate Population Of Advanced EGFR-mutant Non-small Cell Lung Cancer Treated With The First-or Second-followed By Third-generation EGFR-TKI
10.	Influence Of ACK1 Inhibitor On Drug Sensitivity To Osimertinib In EGFR Mutant Non-small Cell Lung Cancer
11.	The Efficacy And Mechanism Of Osimertinib Plus Bevacizumab In Leptomeningeal Metastasis With EGFR Mutant Non-Small Cell Lung Cancer
12.	Survival And Prognosis Analyses Of Concurrent PIK3CA Mutations In EGFR Mutant Non-small Cell Lung Cancer Treated With EGFR Tyrosine Kinase Inhibitors
13.	Predictive Factors And Acquired Resistance For EGFR-TKI Plus Bevacizumab As First-line Treatment In Patients With EGFR Mutant Non-small Cell Lung Cancer
14.	Treatment Of Advanced EGFR-mutant Non-small-cell Lung Cancer:A Single-center Experience
15.	Exploration Of The Value And Mechanism Of TP53 Gene As A Predictive Biomarker For Targeted Therapy And Immunotherapy In Non-small Cell Lung Cancer
16.	The Efficacy And Safety Of Third-generation EGFR-TKIs Combined With Bevacizumab And Intrathecal Pemetrexed In The Treatment Of Leptomeningeal Metastasis With EGFR Mutant Non-small Cell Lung Cancer
17.	The Correlation Between Preoperative C-reactive Protein/prealbumin Ratio And Prognosis Of EGFR-mutant Non-small Cell Lung Cancer
18.	Effects And Mechanisms Of E-cadherin Mediated Immune Escape In EGFR-mutant Non-small Cell Lung Cancer
<<First <Prev Next> Last>> Jump to